While targeting methylation offers therapeutic potential, it is not without challenges. One major issue is the specificity of treatment. Demethylating agents can affect both cancerous and normal cells, leading to potential side effects. Another challenge is the heterogeneity of methylation patterns across different types of cancer and even within the same tumor.
